News List

BeiGene Announces EMA Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with WM
2021-02-25

On June 18, 2020, BeiGene, Ltd. (“BeiGene” or the “Company”), a commercial-stage biotechnology compa

VISEN Pharmaceutical's TransCon C-type natriuretic peptide Phase II clinical trial application approved in China
2021-02-09

January 7, VISEN Pharmaceuticals announced that it had submitted TransCon CNP (TransCon C-type natri

Progress in the development of new and efficient diabetes treatment drugs
2021-01-20

Recently, Wang Junfeng's research team from Hefei Institute of Material Science, Chinese Academy

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA
2020-12-22

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S.

Merck's new HIV drug Pedro (Doravirin) was approved in China
2020-12-09

Merck announced recentlythat its new HIV drug Pedro (doravirin tablets) has been officially approved

ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV
2020-10-18

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shion

European Commission Grants Marketing Authorization for Jyseleca® ▼ (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis
2020-09-28

Gilead Sciences and Galapagos NV today announced that the European Commission (EC) has granted marke